NASDAQ · NTLA
Intellia Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NTLA: Nov 5, 2026
Intellia Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.82. The reported EPS for the same quarter last year was $-0.92.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.82 | $-0.72 | $-0.89 | 7 |
| Dec 2026 | $-0.78 | $-0.41 | $-0.96 | 6 |
| Mar 2027 | $-0.85 | $-0.81 | $-0.95 | 4 |
| Jun 2027 | $-0.79 | $-0.68 | $-0.88 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · The Motley Fool · MarketBeat- Zacks · Oct 29, 4:35 PM EDTExelixis (EXEL) Surpasses Q3 Earnings and Revenue EstimatesExelixis (EXEL) delivered earnings and revenue surprises of +5.62% and +0.86%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 28, 6:50 AM EDTBiogen Inc. (BIIB) Tops Q3 Earnings and Revenue EstimatesBiogen (BIIB) delivered earnings and revenue surprises of +27.18% and +8.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 21, 8:06 AM EDTThe Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking TherapeuticsBridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.
- Zacks · Oct 20, 9:30 AM EDT4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowBBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
- RTTNews · Oct 13, 9:46 AM EDTIntellia Therapeutics Names New CMO To Oversee Clinical And Regulatory Functions(RTTNews) – Intellia Therapeutics, Inc. (NTLA) has appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026.
- Zacks · Oct 9, 6:51 AM EDTIntellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- The Motley Fool · Sep 27, 12:50 PM EDTCould This Cathie Wood Stock Soar in 2027?Intellia Therapeutics could earn its first regulatory approval next year.
- MarketBeat · Sep 19, 12:02 AM EDTIntellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances3 Biotech Stocks That Could Benefit from the Patent CliffIntellia Therapeutics (NASDAQ:NTLA) executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company’s ongoing Phase III program in transthyretin amyloidosis and
- Zacks · Sep 18, 9:44 AM EDTCan Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
- Zacks · Sep 9, 10:05 AM EDTFDA Accepts & Gives Priority Review to Intellia's BLA for HAE DrugNTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
- Zacks · Sep 8, 12:46 PM EDT3 Promising Genomics Stocks in the Spotlight in 2026Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
- RTTNews · Sep 8, 10:54 AM EDTIntellia's Lonvo-z BLA Gets FDA Priority Review For Hereditary Angioedema; PDUFA Set For March 2027(RTTNews) – Intellia Therapeutics (NTLA) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) and granted Priority Review for lonvoguran ziclumeran (lonvo-z) in the treatment of hereditary angioedema.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Intellia Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.